252003-65-9 Usage
Uses
Used in Pharmaceutical Industry:
CP-547632 is used as an anti-cancer agent for its ability to inhibit the growth of solid tumors by targeting VEGFR2 and bFGF, which play crucial roles in angiogenesis and tumor progression.
Used in Drug Development:
CP-547632 is used as a lead compound in the development of novel therapeutics for cancer treatment, particularly for targeting receptor tyrosine kinases involved in tumor growth and angiogenesis.
Used in Research Applications:
CP-547632 serves as a valuable research tool for studying the role of VEGFR2 and bFGF in various cellular processes, including cell proliferation, migration, and angiogenesis, as well as for investigating the mechanisms of action of potential anti-cancer drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 252003-65-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,2,0,0 and 3 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 252003-65:
(8*2)+(7*5)+(6*2)+(5*0)+(4*0)+(3*3)+(2*6)+(1*5)=89
89 % 10 = 9
So 252003-65-9 is a valid CAS Registry Number.
252003-65-9Relevant academic research and scientific papers
PROCESSES FOR THE PREPARATION OF ISOTHIAZOLE DERIVATIVES
-
Page/Page column 34, (2008/06/13)
Processes and intermediates for the preparation of compounds of the Formula (1) and the pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, wherein R1, R2, and R3 have the definitions provided herei
Dosage forms and methods of treatment using VEGFR inhibitors
-
Page/Page column 6, (2008/06/13)
The invention provides dosage forms of a compound of formula 1: or pharmaceutically acceptable salts, solvates or prodrugs thereof. The invention further provides methods of treating hyperproliferative diseases, such as cancers, by administering the dosag
Isothiazole derivatives useful as anticancer agents
-
, (2008/06/13)
The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2and R3are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.
